Aborted myocardial infarction: a new target for reperfusion therapy

Area of Science:

• Cardiology
• Emergency Medicine
• Clinical Trials

Background:

• Reperfusion therapy for ST-elevation acute coronary syndromes (STE-ACS) aims to restore blood flow to salvage heart muscle and improve outcomes.
• Myocardial necrosis is typically assessed by elevated cardiac enzyme levels in plasma.
• A significant minority of patients treated with reperfusion do not show enzyme rise but exhibit ECG changes indicative of aborted myocardial infarction.

Purpose of the Study:

• To evaluate the incidence and significance of aborted myocardial infarction as a potential endpoint in clinical trials for STE-ACS.
• To highlight the association between early reperfusion and the occurrence of aborted infarction.

Main Methods:

• Analysis of reperfusion therapy outcomes in patients with STE-ACS.
• Assessment of myocardial necrosis via enzyme release and electrocardiogram (ECG) changes.
• Correlation of treatment timing with the incidence of aborted infarction and ST-segment resolution.

Main Results:

• Over 10% of patients receiving reperfusion therapy experience an aborted myocardial infarction, characterized by transient ECG changes without significant enzyme elevation.
• Earlier initiation of reperfusion therapy, especially within the first hour of symptom onset, increases the incidence of aborted infarction.
• Treatment within one hour can result in up to 25% aborted infarction, which, combined with complete ST-segment resolution, is linked to improved survival.

Conclusions:

• Aborted myocardial infarction is a frequent outcome of early reperfusion therapy in STE-ACS.
• This endpoint is easily defined, occurs promptly, and is associated with favorable outcomes.
• The study suggests considering 'aborted infarction' as a valuable endpoint in clinical trials for STE-ACS, particularly as other endpoints like mortality decline.